EW - Edwards Lifesciences Corporation
| Previous Close | 176.12 |
| Open | 177.89 |
| Bid | 173.35 x 800 |
| Ask | 194.04 x 800 |
| Day's Range | 176.30 - 178.62 |
| 52 Week Range | 123.00 - 178.62 |
| Volume | 857,379 |
| Avg. Volume | 1,276,767 |
| Market Cap | 37.165B |
| Beta (3Y Monthly) | 0.90 |
| PE Ratio (TTM) | 52.60 |
| EPS (TTM) | 3.38 |
| Earnings Date | Apr 22, 2019 - Apr 26, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 176.76 |
- PR Newswire•3 days ago
CAS MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CAS Medical Systems, Inc. - CASM
NEW ORLEANS , Feb. 15, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...
- Zacks•5 days ago
Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
- Benzinga•5 days ago
The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...
- GuruFocus.com•5 days ago
Edwards Lifesciences Corp (EW) Chairman & CEO Michael A Mussallem Sold $5.8 million of Shares
Chairman & CEO of Edwards Lifesciences Corp (NYSE:EW) Michael A Mussallem sold 32,800 shares of EW on 02/12/2019 at an average price of $176.9 a share.
- GlobeNewswire•6 days ago
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of CAS Medical Systems, Inc. (CASM) on Behalf of Stockholders and Encourages CASM Investors to Contact the Firm
NEW YORK, Feb. 12, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of CAS Medical Systems, Inc. (NASDAQ: CASM) on.
- Investor's Business Daily•6 days ago
These Medtech Stocks Topped Buy Points — Including An IBD 50 Stock
Edwards Lifesciences stock topped a buy point Tuesday on its $100 million plan to buy Cas Medical Systems. IBD 50 stock PRA Health Sciences also broached an entry point.
- PR Newswire•6 days ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of CAS Medical Systems, Inc.
NEW YORK , Feb. 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against CAS Medical Systems, Inc. (NASDAQ: CASM) and its board of directors for breach of fiduciary duty concerning ...
- Benzinga•6 days ago
CAS Medical Surges As Edwards Lifesciences Agrees To Buy Medtech Company In $100M Deal
CAS Medical is a medical tech company that focuses on non-invasive monitoring of tissue oxygenation in the brain. Edwards will buy CAS Medical in an all-cash transaction for $2.45 per share, or an equity value of about $100 million, according to the terms of the deal.
- GlobeNewswire•6 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of CAS Medical Systems, Inc. to Edwards Lifesciences Corporation is Fair to Shareholders
NEW YORK, Feb. 12, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased CAS Medical Systems, Inc. (“CASMED”.
- MarketWatch•6 days ago
CAS Medical Systems stock rockets to pace Nasdaq gainers after Edwards Lifesciences buyout deal
Shares of CAS Medical Systems Inc. rocketed 54% toward a six-month high in morning trade Tuesday, enough to pace all Nasdaq gainers, after the medical technology company agreed to be acquired by Edwards Lifesciences Corp. in a cash deal valued at $100 million. Under terms of the deal, Edwards will pay $2.45 for each CAS share outstanding, which is 56% above Monday's closing price of $1.57. The deal price implies a $70.7 million market capitalization for CAS. Edwards' stock tacked on 0.7%. "Cerebral oximetry technology provides an important indicator of oxygen levels in the brain, which can enhance clinician decision-making, said Katie Szyman, vice president of critical care at Edwards. "We believe the incorporation of CASMED's FORE-SIGHT technology into Edwards' leading hemodynamic monitoring platform, along with Edwards' predictive analytics capability, will strengthen Edwards' leadership in smart monitoring technologies by providing physicians with a more comprehensive status of their surgical and critically ill patients." CAS shares have not run up 28% over the past three months and Edwards' stock has rallied 18%, while the S&P 500 has gained 0.1%.
- PR Newswire•6 days ago
Edwards Lifesciences Enters Into Agreement To Acquire CASMED
IRVINE, Calif. and BRANFORD, Conn., Feb. 12, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has entered into a definitive merger agreement to acquire CAS Medical Systems, Inc. (CASM) (CASMED), a medical technology company dedicated to non-invasive monitoring of tissue oxygenation in the brain. "Cerebral oximetry technology provides an important indicator of oxygen levels in the brain, which can enhance clinician decision-making," said Katie Szyman, Edwards' corporate vice president, critical care.
- Zacks•6 days ago
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
Style Box ETF report for JHMM
- Simply Wall St.•7 days ago
Should We Worry About Edwards Lifesciences Corporation’s (NYSE:EW) P/E Ratio?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! This article is written for those whoRead More...
- Markit•10 days ago
See what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
Edwards Lifesciences Corp NYSE:EWView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for EW with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding EW totaled $12.42 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•12 days ago
Detailed Research: Economic Perspectives on Edwards Lifesciences, Zimmer Biomet, American Outdoor Brands, Radius Health, Kaman, and FARO Technologies — What Drives Growth in Today's Competitive Landscape
Detailed Research: Economic Perspectives on Edwards Lifesciences, Zimmer Biomet, American Outdoor Br, Feb. 06, 2019 -- In new independent research reports released early this.
- Thomson Reuters StreetEvents•16 days ago
Edited Transcript of EW earnings conference call or presentation 31-Jan-19 10:00pm GMT
Q4 2018 Edwards Lifesciences Corp Earnings Call
- Investopedia•17 days ago
3 Medical Device Stocks Set to Test 52-Week Highs
Medical device stocks remain supported by favorable conditions that should see sales grow. Watch these three stocks for a 52-week breakout.
- Investor's Business Daily•17 days ago
Dow Stocks Lead On Strong Job Growth, But Amazon Weighs On Nasdaq
The Dow Jones industrials rallied 100 points early Friday after a strong jobs report. Amazon stock's Q4 earnings weighed on the Nasdaq composite.
- Benzinga•17 days ago
The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 31) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
- Zacks•17 days ago
Edwards Lifesciences (EW) Q4 Earnings In Line, Revenues Top
Edwards Lifesciences (EW) Q4 results benefit from growth in all the businesses.
Motley Fool•17 days agoEdwards Lifesciences Corp (EW) Q4 2018 Earnings Conference Call Transcript
EW earnings call for the period ending December 31, 2018.
- Zacks•18 days ago
Edwards Lifesciences (EW) Q4 Earnings Meet Estimates
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0.00% and 0.41%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Investor's Business Daily•18 days ago
Edwards Stock Slips On Outlook, But Medtech Giant Tops Expectations
Edwards earnings of $1.17 per share, on an adjusted basis, met analyst expectations for the fourth quarter. Sales of $978 million and $983 million in adjusted sales beat analyst views.
- Associated Press•18 days ago
Edwards Lifesciences: 4Q Earnings Snapshot
The Irvine, California-based company said it had net income of 3 cents per share. Earnings, adjusted for non-recurring costs, were $1.17 per share. The results met Wall Street expectations. The average ...
- Reuters•18 days ago
Edwards Lifesciences beats on revenue but forecast lags estimates
U.S. medical device maker Edwards Lifesciences narrowly topped Wall Street estimates for quarterly revenue on Thursday as it sold more heart monitors, but its outlook for March quarter earnings fell below ...
